SWOG clinical trial number
CTSU/NRG-GU005
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Closed
Abbreviated Title
PIII IGRT and SBRT Vs IGRT and Hypofractionated IMRT
Status Notes
Closed to accrual as of 6/8/2022.
Activated
10/01/2019
Closed
06/08/2022
Research committees
Genitourinary Cancer
Treatment
Radiation Therapy
Eligibility Criteria Expand/Collapse
Please see eligibility criteria in protocol on www.CTSU.org
Other Clinical Trials
SWOG Clinical Trial Number
S2419
Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase